Massimo Puoti
#150,984
Most Influential Person Now
Researcher
Massimo Puoti's AcademicInfluence.com Rankings
Massimo Puoticomputer-science Degrees
Computer Science
#7942
World Rank
#8358
Historical Rank
Machine Learning
#3112
World Rank
#3151
Historical Rank
Artificial Intelligence
#3412
World Rank
#3462
Historical Rank
Database
#4998
World Rank
#5192
Historical Rank
Download Badge
Computer Science
Massimo Puoti's Degrees
- PhD Computer Science University of Milan
- Bachelors Computer Science University of Milan
Similar Degrees You Can Earn
Why Is Massimo Puoti Influential?
(Suggest an Edit or Addition)Massimo Puoti's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EASL Recommendations on Treatment of Hepatitis C 2018. (2018) (2085)
- Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. (2014) (1667)
- EASL Recommendations on Treatment of Hepatitis C 2016. (2017) (1167)
- EASL Recommendations on Treatment of Hepatitis C 2015. (2015) (791)
- Statements from the Taormina expert meeting on occult hepatitis B virus infection. (2008) (784)
- A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma (1998) (558)
- EASL recommendations on treatment of hepatitis C - Final update of the series. (2020) (497)
- Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. (2002) (440)
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
- Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. (2007) (357)
- Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences. (1991) (332)
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection (2018) (324)
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial (2021) (311)
- Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. (2004) (301)
- Update of the statements on biology and clinical impact of occult hepatitis b virus infection. (2019) (285)
- European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults (2008) (270)
- Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. (2002) (255)
- Care of patients with hepatitis C and HIV co-infection. (2004) (254)
- Mortality for liver disease in patients with HIV infection: a cohort study. (2000) (247)
- Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome (2004) (245)
- Natural history of chronic hepatitis B in co-infected patients. (2006) (240)
- Antiretroviral drugs and liver injury. (2008) (228)
- Prophylaxis and treatment of hepatitis B in immunocompromised patients. (2007) (225)
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (2019) (221)
- Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. (2001) (212)
- Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. (2011) (190)
- Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study (2015) (185)
- Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy (2001) (177)
- Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. (2008) (172)
- Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). (2002) (139)
- Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. (2000) (137)
- Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. (2002) (135)
- Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV‐positive persons version 9.0 (2018) (131)
- High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. (2018) (127)
- Severe Hepatotoxicity During Combination Antiretroviral Treatment: Incidence, Liver Histology, and Outcome (2003) (125)
- EASL recommendations on treatment of hepatitis C 2014. (2014) (123)
- Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV‐positive persons (2016) (113)
- Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. (2013) (113)
- Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing (2014) (112)
- HCV infection: pathogenesis, clinical manifestations and therapy. (2008) (112)
- Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. (2011) (110)
- High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials (2012) (104)
- Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection (1992) (103)
- Recommendations on Treatment of Hepatitis C 2015 (2015) (102)
- Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report (2020) (100)
- Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. (2019) (100)
- IL28B polymorphisms, IP‐10 and viral load predict virological response to therapy in chronic hepatitis C (2011) (97)
- Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis (2020) (96)
- Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy (2020) (90)
- Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. (2016) (89)
- Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (2020) (87)
- Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies (2017) (82)
- Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients (2020) (79)
- Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. (2008) (77)
- The Burden of Liver Disease in Human Immunodeficiency Virus-Infected Patients (2012) (77)
- Use of Tumor Necrosis Factor-α-blocking Agents in Hepatitis B Virus-positive Patients: Reports of 3 Cases and Review of the Literature (2009) (73)
- Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. (2000) (73)
- ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. (2017) (70)
- Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. (2011) (70)
- Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption (2010) (70)
- Prospective study of mother‐to‐infant transmission of hepatitis C virus (HCV) infection (1998) (68)
- Erratum: Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel (AIDS (2005) 19 (221-240)) (2005) (68)
- High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia. (1998) (67)
- Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. (2009) (65)
- Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) (2020) (64)
- Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. (2010) (63)
- Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. (2014) (63)
- Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. (2015) (62)
- Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. (2015) (62)
- Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. (2017) (61)
- Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients (2020) (61)
- Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure. (2019) (60)
- Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. (2003) (59)
- Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin (2008) (59)
- Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. (2005) (57)
- Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study (2020) (56)
- Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a (2008) (56)
- Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from an Inter-Cohort Analysis (2006) (49)
- Use of Pegylated Interferons is Associated with An Increased Incidence of Infections during Combination Treatment of Chronic Hepatitis C: A Side Effect of Pegylation? (2004) (48)
- Clonality of B‐cells in portal lymphoid infiltrates of HCV‐infected livers (1998) (47)
- Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. (2001) (46)
- Management of infections in cirrhotic patients: report of a consensus conference. (2014) (45)
- The Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case-Control Study in Italian Hospitals (CloVid) (2020) (44)
- Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. (2021) (44)
- Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage (2020) (43)
- Recommendations on Treatment of Hepatitis C 2018 q European Association for the Study of the Liver ⇑ (2015) (43)
- Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection (2016) (42)
- Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? (2007) (42)
- Vaccinations in patients with multiple sclerosis: A Delphi consensus statement (2020) (42)
- Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort (2005) (40)
- HIV-Related Liver Disease: ARV Drugs, Coinfection, and Other Risk Factors (2009) (40)
- Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients (2012) (39)
- Hepatitis C virus infection among drug addicts in Italy (2012) (37)
- Point-of-care screening, prevalence, and risk factors for hepatitis B infection among 3,728 mainly undocumented migrants from non-EU countries in northern Italy. (2015) (37)
- Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study (2017) (36)
- Natural History of Compensated Viral Cirrhosis in a Cohort of Patients With HIV Infection (2007) (36)
- Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection. (2015) (36)
- Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. (2011) (36)
- Distribution of viral genotypes in Italy determined by hepatitis C virus typing by DNA immunoassay (1994) (36)
- Digestive and Liver Disease (2011) (35)
- Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. (2016) (34)
- Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. (2011) (34)
- Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections? (2001) (34)
- The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients (2011) (34)
- Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study (2017) (33)
- Influence of Genotype 3 Hepatitis C Coinfection on Liver Enzyme Elevation in HIV-1-Positive Patients After Commencement of a New Highly Active Antiretroviral Regimen: Results From the EPOKA-MASTER Cohort (2006) (33)
- Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. (2008) (33)
- Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy (2018) (33)
- Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. (1998) (32)
- Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data (2002) (32)
- Effect of Highly Active Antiretroviral Therapy (HAART) and Hepatitis C Co-Infection on Hyperlipidemia in HIV-Infected Patients: A Retrospective Longitudinal Study (2002) (31)
- Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial (2018) (31)
- Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience (2020) (31)
- Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) (2012) (30)
- Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. (2003) (30)
- Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens (2007) (30)
- Impact of hepatitis C virus infection on lifestyle. (2007) (29)
- Evaluation of hepatitis delta virus RNA levels during interferon therapy by analysis of polymerase chain reaction products with a nonradioisotopic hybridization assay (1992) (28)
- Clinical significance of serum hepatitis C virus (HCV) RNA as marker of HCV infection (1994) (27)
- The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement (2020) (27)
- Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals? (2018) (27)
- Optimization of hepatitis C virus screening strategies by birth cohort in Italy (2020) (26)
- HCV chronic hepatitis in patients with HIV: clinical management issues (2002) (25)
- HCV chronic hepatitis in patients with HIV: clinical management issues. (2002) (25)
- Hepatitis C virus genotypes in northern Italy: clinical and virological features (1996) (25)
- Successful recovery from severe COVID‐19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab (2020) (25)
- Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort (2017) (24)
- Viral Interference Between Hepatitis B, C, and D Viruses in Dual and Triple Infections in HIV-Positive Patients (2009) (24)
- ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials (2014) (24)
- Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study (2014) (23)
- Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study (2018) (23)
- Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. (2006) (23)
- Pathogenesis of liver damage in HCV-HIV patients. (2008) (22)
- COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study (2021) (22)
- Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials (2017) (22)
- Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy. (2002) (22)
- The use of molecular assays in the management of viral hepatitis. (2008) (21)
- Risk Factors and Clinical Characteristics Associated with Hospitalization for Community-Acquired Bacterial Pneumonia in HIV-Positive Patients According to the Presence of Liver Cirrhosis (2009) (21)
- SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study (2021) (20)
- Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort (2017) (20)
- The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug? (2004) (20)
- High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis (2017) (19)
- Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study) (2020) (19)
- The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients (2013) (18)
- Hepatocellular carcinoma in HIV hepatitis C virus. (2011) (18)
- Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy (2013) (18)
- Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. (2017) (18)
- Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. (2017) (17)
- Response to pegylated interferon plus ribavirin in HIV‐infected patients with chronic hepatitis C due to genotype 4 (2008) (17)
- Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. (2017) (17)
- Suppression of Hepatitis C Virus Replication is Maintained Long Term following Haart Therapy, in An Individual with HCV/HIV Co-Infection (2004) (17)
- Factors associated with access to antiviral treatment in a multicentre cross‐sectional study of patients with chronic hepatitis B in Italy (2012) (17)
- Evidence of Long-Term Suppression of Hepatitis B virus DNA by Tenofovir as Rescue Treatment in Patients Coinfected by HIV (2008) (16)
- Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality (2020) (16)
- Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials (2019) (16)
- The epidemiological pattern of chronic liver diseases in a community undergoing voluntary screening for hepatitis B and C. (2011) (16)
- Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy (2018) (16)
- Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens (2017) (16)
- Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study (2011) (16)
- Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality (2020) (16)
- Who is more likely to respond to dual treatment with pegylated‐interferon and ribavirin for chronic hepatitis C? A gender‐oriented analysis (2013) (16)
- Clinical Experiences with Interferon As Monotherapy or in Combination with Ribavirin in Patients Co-Infected with HIV and HCV (2002) (15)
- Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. (2017) (15)
- Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? (2007) (15)
- An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. (2015) (15)
- Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort (2020) (15)
- Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients (2018) (15)
- Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? (2021) (15)
- Italian association for the study of the liver position statement on SARS-CoV2 vaccination (2021) (15)
- Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV‐/HCV‐coinfected patients: the role of metabolic factors and elevated GGT levels (2014) (14)
- Neurological manifestations in patients hospitalized with COVID‐19: A retrospective analysis from a large cohort in Northern Italy (2020) (14)
- Eight Weeks Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. (2020) (14)
- Optimizing treatment in HIV/HCV coinfection. (2013) (14)
- Influence of Hepatitis C Genotypes on Lipid Levels in HIV-Positive Patients during Highly Active Antiretroviral Therapy (2005) (14)
- HIV Coinfection and Antiretroviral Therapy Enhances Liver Steatosis in Patients with Hepatitis C, but Only in those Infected by HCV Genotype other than 3 (2008) (14)
- Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. (2002) (14)
- Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy (2009) (13)
- Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1‐coinfected patients (2015) (13)
- The T-cell receptor repertoires expressed by CD4+ and CD4- large granular lymphocytes derived from the same patients suggest the persistent action of an immune-mediated selection process. (1996) (13)
- Single‐center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients (2018) (13)
- Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. (2019) (13)
- The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic-Clinical Management of HIV-1 Infected Persons (2018) (12)
- HIV/HCV co-infection: natural history. (2003) (12)
- Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. (2015) (12)
- Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy (2009) (12)
- Orthopedic injuries in patients with multiple injuries: Results of the 11th trauma update international consensus conference Milan, December 11, 2017. (2020) (12)
- Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis (2010) (11)
- Chronic hepatitis C in Italy: the vanishing of the first and most consistent epidemic wave. (2013) (11)
- Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. (2009) (11)
- Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month (2000) (11)
- Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus (2015) (11)
- Treating hepatitis C virus in HIV patients: are side effects a real obstacle? (2007) (11)
- The burden of HIV and hepatitis C virus coinfection (2007) (11)
- Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study (2018) (11)
- Top topics in HCV research arena (2012) (10)
- Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. (2020) (10)
- Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART (2018) (10)
- Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. (2019) (10)
- Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program (2016) (10)
- Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C (2021) (10)
- Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients >= 65 Years of Age: Results From Phase 2 and 3 Trials (2014) (10)
- Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1–Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort (2014) (10)
- Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection (2017) (10)
- Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy (2020) (9)
- Antibody response to BNT162b vaccine is almost universal in health care workers. Results from the RENAISSANCE study: REsponse to BNT162b2 COVID-19 vacciNe - short And long term Immune reSponSe evAluatioN in healthCare workErs (2021) (9)
- Hepatitis A in men having sex with men (MSMs) in northern Italy. (2010) (9)
- Real life experiences in HCV management in 2018 (2019) (9)
- A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients☆ (2004) (9)
- Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT) (2014) (9)
- Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs. (2014) (9)
- Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis (2019) (9)
- Predictors of Severe Respiratory Failure in Hospitalized Patients with SARS-CoV-2 Infection: Development and Validation of a Prediction Model (PREDI-CO Study) (2020) (9)
- F.N.16 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS (2010) (9)
- Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis (2018) (9)
- Ultrasound evaluation of hepatic lymph nodes in patients with anti-hepatitis C virus antibody reactivity. (1999) (9)
- Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. (2001) (9)
- HIV-positive to HIV-positive liver transplantation: To be continued. (2019) (9)
- Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. (2016) (9)
- Treatment of chronic hepatitis B: Update of the recommendations from the 2007 (2011) (9)
- Letter: sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV‐infected patients (2013) (8)
- Rhinoscleroma in an immigrant from Egypt: a case report. (2012) (8)
- HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study (2016) (8)
- Alcohol and coffee drinking and smoking habit among subjects with HCV infection. (2009) (8)
- Differential pattern of sequence heterogeneity in the hepatitis C virus E1 and E2/NS1 proteins. (1994) (8)
- Implementation of HCV screening in the 1969–1989 birth‐cohort undergoing COVID‐19 vaccination (2022) (8)
- O322: Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV co-infected patients with HCV GT1-4 infection: the PHOTON-1 and -2 Trials (2015) (8)
- Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? (2018) (8)
- High SVR Rates with Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis (2017) (8)
- Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients (2013) (8)
- Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. (2019) (8)
- Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe—short- And long-term Immune reSponSe evAluatioN in health Care workErs (2021) (7)
- 1009 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS (2010) (7)
- Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. (2017) (7)
- The impact of HIV infection and men who have sex with men status on hepatitis A infection: The experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009‐2016 period (2019) (7)
- Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study (2018) (7)
- Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy (2021) (7)
- Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting. (2017) (7)
- Hepatitis A Virus in men who have sex with men: Need for awareness and vaccination (2018) (7)
- Understanding the Mechanisms of Fibrogenesis in HIV/HCV-Coinfected Patients: Implications for Clinical Practice. (2015) (7)
- Molecular analysis of mixed infection with hepatitis C virus and human immunodeficiency virus in a patient infected simultaneously (1996) (7)
- Safety and Efficacy of Directly Acting Antivirals in 2432 HCV Patients with Advanced Fibrosis: An Interim Analysis of the Lombardia Regional Network for Viral Hepatitis (2016) (7)
- Hyperglycemia in Severe Falciparum Malaria: A Case Report (2012) (7)
- Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program (2019) (7)
- Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients (2020) (7)
- Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy (2014) (7)
- EFFECTIVENESS OF ENTECAVIR FOR THE TREATMENT OF NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS: A LARGE MULTICENTER COHORT STUDY IN CLINICAL PRACTICE (2009) (7)
- A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort (2021) (6)
- Home-based COVID 19 management: A consensus document from Italian general medical practitioners and hospital consultants in the Lombardy region (Italy) (2020) (6)
- Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic (2020) (6)
- Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection (2021) (6)
- Tenofovir disoproxil fumarate in pregnancy: Findings from the antiretroviral pregnancy registry (2009) (6)
- DASABUVIR AND OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: REAL LIFE INTERIM ANALYSIS OF AN ITALIAN MULTICENTRE COMPASSIONATE USE PROGRAM (2016) (6)
- Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases (2018) (6)
- Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy (2013) (6)
- The impact of DAA‐mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort (2021) (6)
- Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort (2020) (6)
- Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease. (2014) (6)
- Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B : a 4-year field practice, multicenter study (2012) (6)
- Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV. (1997) (6)
- Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. (2005) (6)
- Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". (2015) (5)
- Sustained virological response with 16‐week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post‐transplant severe HCV recurrence in HIV (2019) (5)
- Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network. (2016) (5)
- Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. (2015) (5)
- Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study) (2022) (5)
- Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV–HIV Coinfection in Interferon-Naive Patients (2014) (5)
- Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) (2018) (5)
- Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy? (2016) (5)
- Obesity Is One of the Strongest Risk Factor for Respiratory Failure and Death in COVID-19 Patients: A Retrospective Multicentric Cohort Study (2020) (5)
- Quantification of 1,3‐β‐d‐glucan by Wako β‐glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study (2020) (5)
- Erratum: Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: Results from an inter-cohort analysis (Antiviral Therapy (2006) 11 (657-674)) (2006) (5)
- HCV Prevalence in Italy an Epidemiological, Observational, Cross-Sectional, Multicenter Study Participating Centers. (2012) (5)
- Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials (2018) (5)
- Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial (2018) (5)
- FDG-PET imaging in the diagnosis of HIV-associated multicentric Castleman disease: something is still missing. (2012) (5)
- PHARMACOKINETICS OF FALDAPREVIR AND ANTIRETROVIRALS IN PATIENTS WITH HIV/HCV CO-INFECTION (2014) (4)
- Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy (2020) (4)
- OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon‐naïve patients with HIV/HCV genotype 2/3 co‐infection in Italy (2015) (4)
- Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? (2019) (4)
- Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. (2020) (4)
- Cytopenias during Treatment of HIV–HCV-Coinfection with Pegylated Interferon and Ribavirin: Safety Analysis of the OPERA Study (2015) (4)
- Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV (2017) (4)
- Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? (2019) (4)
- Human immunodeficiency virus and hepatitis c virus coinfection: The agenda is full while waiting for new drugs (2013) (4)
- HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients (2018) (4)
- Current and future challenges in HCV: insights from an Italian experts panel (2018) (4)
- Trends in all-cause mortality of hospitalized patients due to SARS-CoV-2 infection from a monocentric cohort in Milan (Lombardy, Italy) (2022) (4)
- Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study (2021) (4)
- Detection of serum hepatitis C virus RNA in acute non-A, non-B hepatitis. (1991) (4)
- Host factors and history of SARS-CoV-2 infection impact the reactogenicity of BNT162b2 mRNA vaccine: results from a cross-sectional survey on 7,014 workers in healthcare. (2021) (4)
- Comment to the Editorial: Liver Biopsy in HIV-Infected Patients with Chronic Hepatitis C: Pros and Cons, by Vincent Soriano and Javier García-Samaniego (2002) (4)
- Results of randomized controlled trial on the impact of prolonged combination anti HCV treatment on relapse rate in HIV/HCV coinfected patients with HCVRNA negativization at the end of a 24–48 weeks course of treatment: The ROMANCE study (2008) (4)
- Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort* (2018) (4)
- Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C (2002) (3)
- SVR12 of 99% Achieved With a Ribavirin-Free Regimen of ABT-450/r/Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients: ACG International Award: 440 (2014) (3)
- Hepatitis C virus infection after renal transplantation: prevalence and course of morphologic lesions. (1998) (3)
- CCR5 deficiency exacerbates T‐cell‐mediated hepatitis in mice — Clinical implications for CCR5 inhibition as antiretroviral therapy (2006) (3)
- Does interval time between liver transplant and COVID-19 infection make the difference? (2020) (3)
- AISF position paper on HCV in immunocompromised patients (2019) (3)
- LP39 : Implications of baseline HCVRNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-week treatment outcomes (2015) (3)
- Algorithm for Individual Prediction of COVID-19 Hospitalization from Symptoms: Development and Implementation Study. (2021) (3)
- News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference. (2017) (3)
- Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort. (2014) (3)
- Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study (2016) (3)
- HCV treatment policy in a real-life cohort (2017) (3)
- Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy (2019) (3)
- HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study (2016) (3)
- Histological damage in liver biopsy specimens from 492 HIV-HCV co-infected patients: A European collaborative study (2003) (3)
- Heterogeneity of the hepatitis C virus genome. (1991) (3)
- Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study (2019) (3)
- OC.03.2 ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS (2010) (2)
- Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies (2017) (2)
- Role of HCV viraemia and HCV genotype in the immune recovery from HAART in a cohort of antiretroviral naïve HIV-infected individuals (2005) (2)
- THU-131-Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks (2019) (2)
- Experimental study on the influence of natural and artificial ventilation on indoor radon concentration (2010) (2)
- Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy (2022) (2)
- F-45 Rapid virologic response (RVR), IL28B single nucleotide polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of sustained virologic response (SVR) in HIV/HCV coinfected patients treated with pegylated interferon and ribavirin (2012) (2)
- International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
- HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection (2016) (2)
- 823 HCV GENOTYPE 2 AND 3 RESPOND DIFFERENTLY TO ANTI HCV TREATMENT (2008) (2)
- Obesity and Dysmetabolic Factors among Deceased COVID-19 Adults under 65 Years of Age in Italy: A Retrospective Case-Control Study (2022) (2)
- 15 TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208 (2010) (2)
- Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study (2018) (2)
- Genotype 3 infection in DAA era: Reports of a real life Northern Italy Network for viral hepatitis after 2 years by the start (2017) (2)
- 916 ENTECAVIR IS AN EFFECTIVE TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY (2009) (2)
- Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject. (2018) (2)
- Sexually Transmitted Hepatitis (2020) (2)
- Treatment of hepatitis C virus genotype 1–infected patients: mission accomplished? (2016) (2)
- Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: A case–control study (2012) (2)
- Letter: sustained virological response and liver healing (2017) (2)
- 420 INTERLEUKIN-28B POLYMORPHISMS, IP-10 AND VIRAL LOAD PREDICT VIROLOGICAL RESPONSE TO THERAPY IN CHRONIC HEPATITIS C UNDER REAL-LIFE CONDITIONS (2011) (2)
- Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). (2016) (2)
- Management of hepatitis C in human immunodeficiency virus-infected patients. (2002) (2)
- Clinical Society ( EACS ) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults (2008) (2)
- P1910 Potential role of TDM in dosing protease inhibtors in HIV–HCV co–infected patients with or without cirrhosis (2007) (2)
- Sex differences in electrolyte imbalances caused by SARS‐CoV‐2: A cross‐sectional study (2021) (2)
- Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study (2021) (2)
- High prevalence of anal papillomavirus infection in men who have sex with men PrEP users (2022) (2)
- 256 BASELINE CHARACTERISTICS AND ON-TREATMENT PREDICTORS OF RESPONSES FROM REAL-WORLD PATIENT COHORTS: INTERIM RESULTS OF THE MULTINATIONAL PROPHESYS COHORTS (2010) (2)
- Beyond cure: preventing and managing the complications of end-stage liver disease (2015) (2)
- 73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHESYS COHORT STUDY (2012) (2)
- Virological Failures to New Direct Acting Antivirals in a Real Life Setting May Require Unconventional Regimens for Re-Treatment (2016) (1)
- HIV/HCV coinfection: an update (2005) (1)
- 548 IMPROVED SURVIVAL OF HEPATOCELLULAR CARCINOMA (HCC) IN HIV-INFECTED PATIENTS WITH UNDETECTABLE HIV RNA (2010) (1)
- F-14Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies (2017) (1)
- A phase 3 study to evaluate the efficacy and safety of reparixin in severe COVID-19 pneumonia (2022) (1)
- THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy (2019) (1)
- Reply to Bruno et al.: update to HIV–hepatitis C virus consensus guidelines (2004) (1)
- Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy (2013) (1)
- Feasibility of all-oral anti-HCV treatment during DHAP chemotherapy and autologous stem cell transplantation for T-cell lymphoma. (2018) (1)
- THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients (2019) (1)
- Polymorphic immune restoration syndrome after effective HAART (2003) (1)
- Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics (2018) (1)
- Implementation of hcv screening in the 1969-1989 birth-cohort undergoing covid-19 vaccination: a pivotal study in Italy (2022) (1)
- 773 HIGHER RIBAVIRIN DOSES ARE ASSOCIATED WITH A BETTER RVR IN HIV INFECTED PATIENTS TREATED WITH PEGYLATED INTERFERON IN COMBINATION WITH RIBAVIRIN FOR CHRONIC HEPATITIS C (2008) (1)
- 1065 IMPACT OF SCREENING FOR HEPATOCELLULAR CARCINOMA (HCC) IN HIV/HCV-COINFECTED PATIENTS ON STAGING, THERAPY AND SURVIVAL (2010) (1)
- Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients (2019) (1)
- Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation. (2022) (1)
- In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy (2022) (1)
- 814 OLDER AGE IS ASSOCIATED WITH AN IMPAIRED RESPONSE TO COMBINATION PEGYLATED INTERFERON AND RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C IN A CASE CONTROL STUDY (2008) (1)
- Liver fibrosis progression in patients with hepatitis C, with and without HIV infection (1998) (1)
- Antiretroviral Therapy in HIV/HCV Co-Infection Italian Consensus Workshop (2013) (1)
- P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing (2015) (1)
- Faldaprevir plus pegyliertes Interferon alpha-2a und Ribavirin (PR) bei Patienten mit HIV und Hepatitis C Genotyp (GT)-1 Koinfektion: End of Treatment Response (ETR) – Ergebnisse der Phase III Studie STARTVerso 4 (2014) (1)
- POSTER PRESENTATIONS: Posters Friday, 21 April 2017: Viral hepatitis: Hepatitis C – Clinical (therapy)FRI-279 - Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort (2017) (1)
- Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. (2020) (1)
- Reply to: Epidemiological evidence for an association between higher influenza vaccine uptake in the elderly and lower COVID‐19 deaths in Italy (2021) (1)
- Insulin resistance is not a relevant predictor of sustained virologic response in chronic hepatitis C patients: results from the Italian hepatitis C cohort study (ITAHECS) collaborative group (2009) (1)
- Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel: Erratum. (2020) (1)
- Risk factors for community-acquired bacterial meningitis: men who have sex with men (MSM) as a population at risk for meningococcal nasopharyngeal carriage (2019) (1)
- Common epidemiological distribution of HCV type I and HIV in northern Italy (1993) (1)
- THU-180-Treatment of genotype 3 HCV infection in the large real-life “Navigatore Lombardia” multicentre cohort: Results from three different regimens (2019) (1)
- Natural HCV resistance is common in Italy and differently associated to genotypes (2017) (1)
- 1011 Occurrence of infections during combination treatment with interferons and ribavirin for chronic hepatitis C: role of neutropenia and of interferon pegylation (2003) (1)
- Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection (2021) (1)
- Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis (2005) (1)
- Intrahospital COVID‐19 infection outbreak management: Keep calm and carry on (2021) (1)
- Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection. (2021) (1)
- The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution (2017) (1)
- HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients (2020) (1)
- Hepatitis viruses and liver failure related deaths in human immunodeficiency virus infected patients (1998) (1)
- Post-surgical Hidden Costs: Infections (2019) (1)
- Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment (2016) (1)
- Sex differences in electrolyte imbalances caused by SARS-CoV-2: a case-control study (2021) (1)
- Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy (2021) (1)
- 790 HEPATITIS C TREATMENT OUTCOMES AND PREDICTORS OF RESPONSE IN TREATMENT-NAIVE PATIENTS TREATED WITH PEGINTERFERON alfa/RIBAVIRIN IN REAL-WORLD ITALIAN CLINICS COMPARED WITH OTHER COUNTRIES: PROPHESYS SUB-ANALYSIS (2013) (1)
- Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program. (2017) (1)
- [Update on the diagnosis and therapy of blood-transmitted occupational infections]. (2010) (1)
- Algorithm for Individual Prediction of COVID-19–Related Hospitalization Based on Symptoms: Development and Implementation Study (2021) (1)
- In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment (2016) (1)
- 732 EFFICACY AND TOLERANCE OF TENOFOVIR IN SUBOPTIMAL RESPONDERS TO ADV OR ADV/LAM TREATMENT: 96 WEEKS RESULTS OF THE OPTIB ITALIAN MULTICENTER PROSPECTIVE OPEN LABEL STUDY (2011) (0)
- Development and external validation of a diagnostic multivariable prediction model for a prompt identification of cases at high risk for SARS-COV-2 infection among patients admitted to the emergency department (2021) (0)
- 860 REVISTING PREDICTORS OF VIROLOGIC RESPONSE TO PEGIFN+RBV THERAPY IN HIV/HCV COINFECTED PATIENTS: THE ROLE OF METABOLIC FACTORS AND ELEVATED GGT LEVELS (2013) (0)
- Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort (2015) (0)
- F-42 OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance (2011) (0)
- Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? (2018) (0)
- Genotype 3 infection in DAA era: Preliminary reports of a real life northern Italy network for viral hepatitis (2016) (0)
- Excellent effectiveness of direct-acting antivirals for HCV treatment in patients with cirrhosis: Analysis of 3345 patients from the Lombardia Network (2018) (0)
- Trends in chronic Hepatitis B virus infection in Italy over a 10-year period: clues from the nationwide PITER and MASTER cohorts towards elimination. (2023) (0)
- The hepatitis C continuum of care among HIV infected individuals in the Icona study network (2018) (0)
- Resistance and phylogenetic analysis in HCV-2c infected patients within the Italian network VIRONET-C (2020) (0)
- SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT (2014) (0)
- Targeted screening for viral epatiti in an italian community of 100.000 inhabitants (2009) (0)
- 1088 RATES AND PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE AND RELAPSE IN ITALIAN NAIVE MONO-INFECTED CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON ALFA/RIBAVIRIN: PROPHESYS 2 FINAL ANALYSIS (2012) (0)
- Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study (2018) (0)
- 5 May HCV VL or HCV genotype affect the immune response after starting HAART in HCV/HIV co-infected subjects? (2003) (0)
- High SVR Rates with 8 and 12 Weeks of Pangenotypic GlecapreviriPibrentasvir: PH2Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis (2017) (0)
- Prevalence and clinical outcome of hepatitis Delta infection in patients with HIV/HBV coinfection (2018) (0)
- 609 BASELINE CHARACTERISTICS AND WEEK-4 RESPONSE AMONG 1546 CHC PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 AND 4: INTERIM RESULTS OF THE PROPHESYS COHORT (2009) (0)
- Announcements and Call for Abstracts (2009) (0)
- Patients with HIV-HBV coinfection are an underestimated reservoir for Hepatitis Delta Virus. An analysis of the ICONA cohort (2016) (0)
- VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen (2020) (0)
- [Treatment of HCV infection in HIV-positive patients]. (2001) (0)
- Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group (2018) (0)
- CONCISE COMMUNICATION Liver Damage and Kinetics of Hepatitis C Virus and Human Immunodeficiency Virus Replication during the Early Phases of Combination Antiretroviral Treatment (0)
- Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network (2018) (0)
- Corrigendum to: “Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)” Clinical Microbiology and Infection 26 (2020) 1545e–1553 (2023) (0)
- F-43 A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral tretament with interferon and ribavirin in daily clinical practice (2011) (0)
- Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort. (2023) (0)
- Incidence and risk factors for liver enzyme elevation during antiretroviral therapy in HIV / HCV coinfected patients RUNNING HEAD : Hepatotoxicity in HIV / HCV coinfection (2005) (0)
- F-02 Incidence and consequences of thrombocytopenia in 1523 HIV/HCV coinfected patients treated with PEGylated interferon and ribavirin (2013) (0)
- Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study (2019) (0)
- Algorithm for Individual Prediction of COVID-19 Hospitalization from Symptoms: Development and Implementation Study (Preprint) (2021) (0)
- “De novo” combination with adefovir and lamivudine is more effective than adefovir “add on” and as effective as lamivudine monotherapy in antiviral treatment of chronic HBV infection (2008) (0)
- INTRAHEPATIC HCV REPLICATION IN PATIENTS WITH HCV RELATED LIVER CIRRHOSIS (2009) (0)
- Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C (2020) (0)
- Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program (2019) (0)
- What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres (2022) (0)
- HIV-Positive Donors to HIV-Positive Transplant Recipients: The Italian Experience. (2018) (0)
- 862 THE IMPACT OF IL28B rs12979860 SNP ON THE ASSOCIATION BETWEEN TREATMENT DURATION AND SUSTAINED VIROLOGIC RESPONSE IN HIV/HCV COINFECTED PATIENTS (2013) (0)
- OC-34 OPERA: the use of Pegylated interferon and ribavirin for the treatment of HCV/HIV coinfection in interferon-naïve patients in Italy (2013) (0)
- Epidemiological, virological and clinical profile of HBsAg positive individuals in Italian hospital settings: interim results of the HBV/HDV PITER cohort (2022) (0)
- COVID-19 in Liver Transplant Candidates: Pre- and Post-Transplant Outcome (2021) (0)
- HCVRNA increase during antiretroviral treatment (ART) induced HIVRNA rapid phase decline: An evidence of virus-virus interaction? (2000) (0)
- Su1062 Comparisons of Populations in Faldaprevir Phase III Studies Based on Pegylated Interferon α-2A and Ribavirin-Predicted Responsiveness and Impact on Achieving Svr12 (2014) (0)
- Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors (2015) (0)
- 262 Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients (2004) (0)
- Interferon alfa therapy for the anti-HBe positive form of chronic hepatitis B: increased efficacy of a two years course (1998) (0)
- 707 “PROPHYLACTIC” ADEFOVIR “ADD ON” IS ASSSOCIATED WITH A LOWER RATE OF VIROLOGIC BREAKTHROUGH IN PATIENTS WITH OPTIMAL RESPONSE TO LAMIVUDINE AND UNDETECTABLE HBVDNA (2008) (0)
- Impact of HBV infection in HCV/HBV coinfected patients treated with DAAs IN Northern Italy (2020) (0)
- IFN impact on liver disease progression in HBeAg negative chronic hepatitis B (CHB): a long-term italian multicenter AISF study (2005) (0)
- Progression of liver disease in HIV/HCV co-infected people according to gender in the Icona Cohort: role of age as potential different exposure to estrogens (2015) (0)
- Incidence, Temporal Trends, and Predictors of Thrombocytopenia Among HIV-Infected Persons Treated with Combined Antiretroviral Therapy (cART) (2010) (0)
- 1107 PREDICTIVE VALUE OF FIB-4 VS METAVIR ON SUSTAINED VIROLOGICAL RESPONSE IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS: FINAL ANALYSIS FROM THE LARGE MULTINATIONAL PROPHESYS TRIAL (2012) (0)
- Impact if HBV infection in HCV/HBV coinfected patients treated with DAAs in north Italy (2020) (0)
- Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease (2008) (0)
- Re-treatment with interferon plus ribavirin of chronic hepatitis C nonresponders to interferon monotherapy: A meta-analysis of individual patient data (2001) (0)
- Visceral Leishmaniasis and Pegylated Interferon. Author’s reply (2005) (0)
- End stage liver disease (ESLD) as the most frequent cause of death in HIV seropositives: results of a prospective cohort study (2001) (0)
- Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy (2018) (0)
- Incidence and risk factors for liver enzyme elevation during 1 highly active antiretroviral therapy in HIV-HCV co-infected patients : 2 results from the Italian EPOKA-MASTER Cohort 3 4 (2005) (0)
- 56 Featuring HIV / HCV coinfected women in the Icona Cohort : epidemiological and clinical aspects according to gender (2014) (0)
- Older age is associated with an impaired response to combination pegylated interferon and ribavirin treatment for chronic hepatitis C (2008) (0)
- Electrophysiological Adverse Effects of Direct‐Acting Antivirals in Patients With Chronic Hepatitis C (2017) (0)
- Transient elastography (TE) as a tool to evaluate acute liver damage: A prospective, multicentric cohort study (2008) (0)
- HCV genotype 2 and 3 respond differently to anti HCV treatment (2008) (0)
- HIV/HCV co-infected subjects show better thrombocytopenia improvement after sustained virologic response achievement than HCV mono-infected cirrhotics. Data from the hepaiCONA and PITER cohorts. (2020) (0)
- Cases From the Field FDG-PET Imaging in the Diagnosis of HIV-Associated Multicentric Castleman Disease : Something Is Still Missing 116 (2012) (0)
- T-34 Interleukin-28B polymorphisms, IP-10, viral load and age predict the outcome of therapy in genotype 1 hepatitis C virus under real-life conditions (2011) (0)
- Genotype 3 Infection in HIV/HCV co-infected subjects in the DAA era: Real life data from the ICONA/HepaICONA Foundation cohorts (2018) (0)
- THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance (2019) (0)
- What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres (2022) (0)
- Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection. (2023) (0)
- The old patient in DAA era: Real life reports on 5925 patients from the Lombardy HCV Network (2017) (0)
- Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy (2018) (0)
- Nucleos(t)ide Analogue Based Therapy and Management of Patients (2016) (0)
- Members of the Italian Cohort Naive for Antiretrovirals-Hepatitis Study Group. (2005) (0)
- P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS (2014) (0)
- Challenges in HCV Elimination. (2017) (0)
- Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. (2011) (0)
- F-10 Treatment outcomes and predictors of response in treatment-naive hepatitis C patients treated with Peg-interferon alpha/ribavirin in real-world Italian clinics: PROPHESYS sub-analysis (2013) (0)
- Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi (2023) (0)
- 825 RESULTS OF A RANDOMIZED CONTROLLED TRIAL ON THE IMPACT OF PROLONGED COMBINATION ANTI-HCV TREATMENT IN HIV/HCV CO-INFECTED PATIENTS (2008) (0)
- Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection (2022) (0)
- Safety and efficacy of Daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA Foundation cohorts (2018) (0)
- T1987 Baseline Characteristics and on-Treatment Predictors of Response Among Patients With Chronic Hepatitis C: Interim Results From Real-World Patient Cohorts (Prophesys) (2010) (0)
- Interleukin-28B polymorphisms, IP-10, viral load and age predict the outcome of therapy in genotype 1 hepatitis C virus under real-life conditions (2011) (0)
- 861 THE IMPACT OF IL28B rs12979860 SNP AND ADVANCED LIVER FIBROSIS ON RESPONSE-GUIDED THERAPY IN HIV/HCV COINFECTED PATIENTS OF PARTICULAR CLINICAL INTEREST (2013) (0)
- 16 PREVALENCE AND RISK FACTOR OF HBV INFECTION AMONG 4959 IMMIGRANTS FROM NON EU COUNTRIES IN ITALY (2010) (0)
- [PP.27.11] 24 HOUR ARTERIAL DISTENSIBILITY IS RELATED WITH ABPM NON-DIPPING PATTERN IN HIV-POSITIVE PATIENTS (2016) (0)
- HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico (2015) (0)
- 24-Hour Blood Pressure Monitoring Patterns in HIV-Positive Patients and its Relationship with Arterial Distensibility (2016) (0)
- Screening strategies for Hepatitis C Virus elimination in Italy (2019) (0)
- THU-397-Screening strategies for hepatitis C virus elimination in Italy (2019) (0)
- Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1 positive patients after commencement of a new highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER COHORT (2005) (0)
- PGI44 SCREENING STRATEGIES FOR HEPATITIS C VIRUS ELIMINATION IN ITALY (2019) (0)
- THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience (2019) (0)
- THU-128-Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study (2019) (0)
- 4 HIV accelerates occurrence and increases invasiveness of hepatocellular carcinoma (HCC) (2003) (0)
- Managing hepatitis C virus-HIV liver transplant recipients with the new direct-acting antivirals: are we glimpsing a brilliant future behind our shoulders? (2016) (0)
- Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy (2017) (0)
- Is the increased risk of liver enzyme elevation in hepatitis co-infected patients greater in those on HAART than in antiretroviral-naïve patients? (2006) (0)
- HCV carriers with normal alt: healthy people or patients with chronic hepatitis? The Italian study of the asymptomatic C carriers (ISACC) (2001) (0)
- Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. (2015) (0)
- Sequence heterogeneity of the hepatitis C virus envelope region. Implications for the location of predicted antigenic determinants. (1991) (0)
- Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di) (2023) (0)
- Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy (2018) (0)
- Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance? (2014) (0)
- Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy (2017) (0)
- SAT0460 HCV-RELATED MIXED CRYOGLOBULINAEMIA IN THE DIRECT-ANTIVIRAL AGENTS ERA: IS THERE ADVANTAGE IN SEQUENTIAL THERAPY WITH RITUXIMAB? (2019) (0)
- Impaired renal function but high sustained virological response (SVR) rates in hepatitis C virus (HCV) elderly treated with direct-acting antivirals (DAA): A report from the Lombardy Network (2018) (0)
- Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks (2019) (0)
- P1122 COMPARISONS OF POPULATIONS IN FALDAPREVIR PHASE III STUDIES BASED ON PEGYLATED INTERFERON a-2a AND RIBAVIRIN-PREDICTED RESPONSIVENESS AND IMPACT ON ACHIEVING SVR12 (2014) (0)
- Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers (2022) (0)
- Acute HCV Infection: Diagnosis, Epidemiology and Current Treatment Options (2015) (0)
- Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study. (2023) (0)
- HEV infection: an emerging disease. One year observation in a tertiary care center in Milan (2019) (0)
- Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents (2016) (0)
- F-04 Incidence, predictors and management strategies of anemia in HIV/HCV coinfected patients treated with PEGylated interferon and ribavirin (2013) (0)
- Biphasic Kinetics of HCV-RNA Decay is Accompanied by an even Faster Aminotransferases Normalization in All-Daa Treated Cirrhotic Patients: A Different Scenario from Interferon-Based Therapies (2016) (0)
- Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunode fi ciency virus * Clinical Microbiology and Infection (2017) (0)
- Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance (2019) (0)
- Evolution and Determinants of the Prevalence of HCV Infection and Hcv Genotype Distribution among Hivinfected Patients Entering in Care between 1997–2015 in Italy: Data from a Prospective Nationwide Cohort (ICONA) (2016) (0)
- 604 Fibrosis progression in 914 HIV-HCV co-infected patients is strongly related with age: an European collaborative study (2003) (0)
- Durability and tolerability of first-line combination including two NRTI and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation cohort (2016) (0)
- (210) – First Outbreak of Pneumocystis jirovecii Pneumonia in Heart Transplantation Recipients (2017) (0)
- Treatment of chronic hepatitis C in Lombardia: An analysis on the safety and efficacy of DAA therapy in 5457 patients (2017) (0)
- The role of intravenous immunoglobulin in the treatment of community-acquired West Nile virus encephalitis after liver transplantation. (2023) (0)
- 240 Similar Adjusted Svr12 Rates for HIV Co-Infected and HCV Mono-Infected Patients and No Dose or Population (Treatment-Naïve/Relapser) Effect: Pooled Analysis of Faldaprevir Phase III Trials (2014) (0)
- Virological characterization of patients with chronic hepatitis C and failure to a glecaprevir/pibrentasvir or voxilaprevir/ velpatasvir/sofosbuvir treatment in the international shared collaboration (2020) (0)
- Triglycerides / HDL Ratio And Its Impact On Risk Of Diabetes Mellitus Development During 1 Antiretroviral Therapy 2 Short running title : Triglycerides / HDL Ratio and Diabetes ' risk 3 (2017) (0)
- M1812 Baseline Characteristics and Week-4 Response Among 1546 CHC Patients Infected with HCV Genotype 1, 2, 3 and 4: Interim Results of the Prophesys Cohort (2009) (0)
- 421 FIB-4 SCORE IS A STRONGER PREDICTOR OF VIROLOGICAL RESPONSE THAN LIVER BIOPSY (METAVIR) IN HEPATITIS C GENOTYPE 1 PATIENTS: INTERIM DATA FROM THE PROPHESYS TRIAL (2011) (0)
- persistent action of an immune-mediated selection process granular lymphocytes derived from the same patients suggest the The T-cell receptor repertoires expressed by CD4+ and CD4- large (2011) (0)
- The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated HCV virus infection: An interim analysis in the PITER cohort (2020) (0)
- Occult Hepatitis B virus and hepatocellular carcinoma: a case-control study. (2005) (0)
- Forecasting liver disease burden (2018) (0)
- Hepatitis Delta in HIV: changes in attitude to testing and disease burden over time (2022) (0)
- Liver transplantation in HIV-positive patients: The initial experience (2016) (0)
- Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals. (2023) (0)
- Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy (2022) (0)
- “Prophylactic” adefovir “add on” is associated with a lower rate of virologic breakthrough in patients with optimal response to lamivudine and undetectable HBV–DNA (2008) (0)
- Integrated efficacy and safety analysis of GT1-6 treatment-naive, non-cirrhotic and compensated cirrhotic patients who received 8 weeks of glecaprevir/pibrentasvir (2020) (0)
- O233 Surrogate markers for liver damage (i.e. how can we measure the extent of fibrosis and disease without biopsy) (2008) (0)
- R2297 Pharmacokinetics of atazanavir in HIV-HCV co-infected patients with or without cirrhosis (2007) (0)
- The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated chronic hepatitis C viral infection: an interim analysis in the PITER cohort (2020) (0)
- 824 ABACAVIR HAS A NEGATIVE IMPACT ON RAPID VIROLOGIC RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRRIN COMBINATION TREATMENT OF HEPATITIS C IN HIV-1 COINFECTED PATIENTS (2008) (0)
- F-42 Gender-specific determinants of response in HCV genotype 1 to current SOC with peg IFN and ribavirin in a practice cohort (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Massimo Puoti?
Massimo Puoti is affiliated with the following schools:
